Trial Profile
Open-label, randomized, single-dose, two-cohort crossover study in healthy volunteers assessing bioavailability and pharmaceutical properties of novel buprenorphine/naloxone sublingual tablet
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 02 Dec 2018
Price :
$35
*
At a glance
- Drugs Buprenorphine/naloxone (Primary)
- Indications Opioid-related disorders
- Focus Pharmacokinetics
- 02 Dec 2018 New trial record